- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07807176
Neuromodulation Combined With Dual FES Cycling and Cognitive Training After Stroke
Exploratory Evaluation of Neuromodulation Combined With Dual Functional Electrical Stimulation Cycling and Cognitive Task Training on Cognitive-Motor Performance in Individuals After Stroke
This study will evaluate the effects of functional electrical stimulation (FES) cycling, cognitive task training, and non-invasive photobiomodulation on cognitive and upper-limb motor performance in adults after stroke. The study includes three stages to identify favorable FES cycling and neuromodulation approaches and to evaluate their combined effects. Participants will complete 10 intervention sessions over 2 weeks. Cognitive and motor outcomes will be assessed before treatment, immediately after treatment, and at 3-month follow-up. Feasibility, tolerance, and adverse events will also be evaluated.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
- Přístroj: Functional Electrical Stimulation Cycling
- Behaviorální: Cognitive Task Training
- Přístroj: Sham Functional Electrical Stimulation Cycling
- Přístroj: Transcutaneous Auricular Photobiomodulation
- Přístroj: Transcutaneous Forehead Photobiomodulation
- Přístroj: Sham Photobiomodulation
- Jiný: Optimal FES Cycling Protocol
- Přístroj: Optimal Neuromodulation Protocol
Detailní popis
This is a three-stage, randomized, sham-controlled study in individuals after stroke. Stage 1 will compare FES cycling alone, FES cycling combined with cognitive task training, and sham FES cycling. Stage 2 will compare photobiomodulation applied to the ear, forehead, and sham stimulation. Stage 3 will evaluate the selected FES cycling and neuromodulation approaches alone and in combination. Participants will complete 10 sessions over 2 weeks. Cognitive, upper-extremity motor, functional, participation, and quality-of-life outcomes will be assessed at baseline, immediately after treatment, and at 3-month follow-up. Feasibility, adherence, tolerance, and adverse events will also be monitored.
Typ studie
Zápis (Odhadovaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
- Jméno: Chia-Ling Chen
- Telefonní číslo: 8148 +883-3-3281200
- E-mail: clingchen@gmail.com
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Adults aged 20 to 80 years.
- First-ever ischemic or hemorrhagic stroke with unilateral impairment in hand or arm strength or motor function.
- Medically stable and able to participate safely in the training program.
- Able to understand the study procedures and sign the informed consent form.
- Able to follow verbal instructions, comply with study procedures, and complete all assessments.
- Able to maintain a seated position and participate in each training session (approximately 40-60 minutes).
Exclusion Criteria:
- Stroke involving the brainstem or cerebellum.
- History of epilepsy, photosensitive epilepsy, or a tendency to faint.
- Presence of implanted electronic devices, such as pacemakers, implantable cardioverter-defibrillators (ICD), or other electronic medical implants (e.g., artificial heart, infusion pumps, cochlear implants).
- Wounds, infections, or significant skin problems at potential stimulation sites (ear or scalp).
- Presence of major psychiatric disorders or inability to understand or cooperate with testing.
- Cardiovascular or vascular-related conditions, including severe heart disease, uncontrolled arrhythmia, or medical advice against exercise; use of anticoagulant medication that makes laser stimulation inappropriate.
- Acute illness, such as fever or active infection.
- Botulinum toxin injections or relevant surgeries within the past six months.
- Photosensitive disorders (e.g., lupus, porphyria) or current use of photosensitizing medications.
- Inability to safely perform cycling training (e.g., recent fractures, severe spasticity, difficulty maintaining seated posture).
- Pregnant or breastfeeding individuals.
- Any other condition deemed unsuitable by the study physician (e.g., severe claustrophobia).
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Dvojnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Stage 1: FES Cycling Alone
Participants receive FES-assisted arm cycling. |
FES-assisted arm cycling is provided for approximately 40 minutes per session, 5 sessions per week for 2 weeks. |
|
Experimentální: Stage 1: Dual-Task FES Cycling
Participants receive FES-assisted arm cycling combined with cognitive task training. |
FES-assisted arm cycling is provided for approximately 40 minutes per session, 5 sessions per week for 2 weeks. Cognitive tasks are performed during FES cycling and progressively target attention, working memory, and executive control. |
|
Komparátor placeba: Stage 1: Sham FES Cycling
Participants receive sham FES cycling. |
Participants receive the sham FES cycling control condition. |
|
Experimentální: Stage 2: Auricular Photobiomodulation
Participants receive transcutaneous auricular photobiomodulation (taPBM). |
Photobiomodulation is applied to the outer ear for approximately 20 to 30 minutes. |
|
Experimentální: Stage 2: Forehead Photobiomodulation
Participants receive transcutaneous forehead photobiomodulation (tfPBM). |
Photobiomodulation is applied to the forehead for approximately 20 to 30 minutes. |
|
Komparátor placeba: Stage 2: Sham Photobiomodulation
Participants receive sham photobiomodulation. |
Participants receive the sham photobiomodulation control condition. |
|
Experimentální: Stage 3: Optimal FES Cycling + Sham Neuromodulation
Participants receive the optimal FES cycling protocol identified in Stage 1 combined with sham neuromodulation. |
Participants receive the sham photobiomodulation control condition. The FES cycling condition associated with the most favorable cognitive-motor performance pattern in Stage 1 will be selected for use in Stage 3. The selected protocol will consist of either FES cycling alone or FES cycling combined with cognitive task training. |
|
Experimentální: Stage 3: Optimal Neuromodulation + Sham FES Cycling
Participants receive the optimal neuromodulation protocol identified in Stage 2 combined with sham FES cycling. |
Participants receive the sham FES cycling control condition. The photobiomodulation condition associated with the most favorable cognitive-motor performance pattern in Stage 2 will be selected for use in Stage 3. The selected protocol will consist of either transcutaneous auricular photobiomodulation (taPBM) or transcutaneous forehead photobiomodulation (tfPBM). |
|
Experimentální: Stage 3: Optimal FES Cycling + Optimal Neuromodulation
Participants receive the optimal FES cycling protocol combined with the optimal neuromodulation protocol. |
The FES cycling condition associated with the most favorable cognitive-motor performance pattern in Stage 1 will be selected for use in Stage 3. The selected protocol will consist of either FES cycling alone or FES cycling combined with cognitive task training. The photobiomodulation condition associated with the most favorable cognitive-motor performance pattern in Stage 2 will be selected for use in Stage 3. The selected protocol will consist of either transcutaneous auricular photobiomodulation (taPBM) or transcutaneous forehead photobiomodulation (tfPBM). |
|
Komparátor placeba: Stage 3: Sham FES Cycling + Sham Neuromodulation
Participants receive sham FES cycling combined with sham neuromodulation. |
Participants receive the sham FES cycling control condition. Participants receive the sham photobiomodulation control condition. |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Trail Making Test-Part B (TMT-B)
Časové okno: Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
|
The TMT-B assesses executive function and cognitive flexibility. Longer completion times indicate poorer executive function and cognitive flexibility. |
Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
|
|
Intra-Extra Dimensional Shift (IED)
Časové okno: Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
|
The IED assesses set-shifting ability and cognitive flexibility. Fewer errors indicate better performance. |
Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
|
|
Rapid Visual Information Processing (RVP)
Časové okno: Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
|
The RVP assesses sustained attention. Higher accuracy indicates better sustained attention. |
Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
|
|
Digit Span Test
Časové okno: Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
|
The Digit Span Test assesses working memory and sustained attention. Higher span scores indicate stronger working memory and sustained attention. |
Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
|
|
Fugl-Meyer Assessment-Upper Extremity (FMA-UE)
Časové okno: Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
|
The FMA-UE assesses upper-extremity motor control. Scores range from 0 to 66, with higher scores indicating better motor control. |
Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
|
|
Action Research Arm Test (ARAT)
Časové okno: Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
|
The ARAT assesses upper-limb functional performance. Scores range from 0 to 57, with higher scores indicating better upper-limb function. |
Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Montreal Cognitive Assessment (MoCA)
Časové okno: Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
|
The MoCA assesses cognitive functioning across domains including attention, executive function, memory, and visuospatial skills. Scores range from 0 to 30, with higher scores indicating better cognitive functioning. |
Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
|
|
Trail Making Test-Part A (TMT-A)
Časové okno: Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
|
The TMT-A assesses processing speed and attention. Longer completion times indicate poorer processing speed and attention. |
Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
|
|
Symbol Digit Modalities Test (SDMT)
Časové okno: Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
|
The SDMT assesses processing speed. More correct responses indicate better processing speed. |
Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
|
|
Spatial Working Memory (SWM)
Časové okno: Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
|
The SWM assesses working memory. Fewer errors indicate better working memory performance. |
Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
|
|
Paired Associates Learning (PAL)
Časové okno: Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
|
The PAL assesses visual learning. Fewer errors indicate better visual learning performance. |
Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
|
|
Modified Ashworth Scale (MAS)
Časové okno: Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
|
The MAS assesses muscle spasticity. Scores range from 0 to 4, with higher scores indicating greater spasticity. |
Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
|
|
Grip and Pinch Dynamometry
Časové okno: Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
|
Grip and pinch dynamometry measures upper-extremity muscle strength. Higher force output indicates greater muscle strength. |
Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
|
|
Box and Block Test (BBT)
Časové okno: Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
|
The BBT assesses gross manual dexterity. More blocks transferred indicate better gross manual dexterity. |
Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
|
|
Nine-Hole Peg Test (9HPT)
Časové okno: Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
|
The 9HPT assesses fine motor coordination. Shorter completion times indicate better fine motor coordination. |
Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
|
|
Motor Activity Log (MAL)
Časové okno: Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
|
The MAL assesses use of the affected arm in daily activities and perceived quality of movement. Scores range from 0 to 5, with higher ratings indicating greater daily arm use and better movement quality. |
Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
|
|
ABILHAND Questionnaire
Časové okno: Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
|
The ABILHAND Questionnaire assesses perceived manual ability in daily activities. Higher logit scores indicate better perceived manual ability. |
Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
|
|
Functional Independence Measure (FIM)
Časové okno: Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
|
The FIM assesses functional independence. Scores range from 18 to 126, with higher scores indicating greater functional independence. |
Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
|
|
Stroke Impact Scale (SIS)
Časové okno: Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
|
The SIS assesses the impact of stroke on functional recovery. Domain scores range from 0 to 100, with higher scores indicating better functional recovery. |
Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
|
|
Stroke-Specific Quality of Life Scale (SS-QOL)
Časové okno: Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
|
The SS-QOL assesses stroke-specific health-related quality of life. Higher scores indicate better health-related quality of life. |
Baseline (T0), immediately after the 2-week intervention (T1), and 3-month follow-up (T2).
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Ředitel studie: Chia-Ling Chen, Chang Gung Memorial Hospital
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 202502050A3
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .